Carisma Therapeutics to Present Groundbreaking Cancer Study at ASCO 2024

Carisma Therapeutics

PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) is set to showcase a pioneering cancer treatment study at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago, IL, from May 31 to June 4.

The company will present a poster on a phase 1, first-in-human study focused on autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in individuals with HER2-overexpressing solid tumors. Slated for the Developmental Therapeutics—Immunotherapy session on June 1, the study, identified as abstract TPS2682, aims to introduce a novel approach in the battle against solid tumors.

Following the presentation, the poster will be accessible online, offering the public insight into Carisma Therapeutics’ innovative research and potential new therapies in oncology.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.

READ:  Tech Pioneer Cantaloupe, Inc. Revolutionizes Self-Service Commerce at National Restaurant Association Show